TY - JOUR AU - Palumbo, A. AU - Anderson, K. PY - 2011 DA - 2011// TI - Multiple myeloma JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMra1011442 DO - 10.1056/NEJMra1011442 ID - Palumbo2011 ER - TY - BOOK AU - Howlader, N. AU - Noone, A. M. AU - Krapcho, M. AU - Miller, D. AU - Bishop, K. AU - Altekruse, S. F. PY - 2016 DA - 2016// TI - SEER Cancer Statistics Review, 1975-2013 PB - National Cancer Institute CY - Bethesda ID - Howlader2016 ER - TY - JOUR AU - Ferlay, J. AU - Steliarova-Foucher, E. AU - Lortet-Tieulent, J. AU - Rosso, S. AU - Coebergh, J. W. AU - Comber, H. PY - 2013 DA - 2013// TI - Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.12.027 DO - 10.1016/j.ejca.2012.12.027 ID - Ferlay2013 ER - TY - JOUR AU - Kim, K. AU - Lee, J. H. AU - Kim, J. S. AU - Min, C. K. AU - Yoon, S. S. AU - Shimizu, K. PY - 2014 DA - 2014// TI - Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study JO - Am J Hematol VL - 89 UR - https://doi.org/10.1002/ajh.23731 DO - 10.1002/ajh.23731 ID - Kim2014 ER - TY - JOUR AU - Zhou, M. AU - Wang, H. AU - Zhu, J. AU - Chen, W. AU - Wang, L. AU - Liu, S. PY - 2016 DA - 2016// TI - Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013 JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)00551-6 DO - 10.1016/S0140-6736(15)00551-6 ID - Zhou2016 ER - TY - JOUR AU - Yang, L. AU - Parkin, D. M. AU - Ferlay, J. AU - Li, L. AU - Chen, Y. PY - 2005 DA - 2005// TI - Estimates of cancer incidence in China for 2000 and projections for 2005 JO - Cancer Epidemiol Biomarkers Prev VL - 14 ID - Yang2005 ER - TY - JOUR AU - Lu, J. AU - Lu, J. AU - Chen, W. AU - Huo, Y. AU - Huang, X. AU - Hou, J. PY - 2014 DA - 2014// TI - Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis JO - Blood Cancer J VL - 4 UR - https://doi.org/10.1038/bcj.2014.55 DO - 10.1038/bcj.2014.55 ID - Lu2014 ER - TY - JOUR AU - Kumar, S. K. AU - Dispenzieri, A. AU - Lacy, M. Q. AU - Gertz, M. A. AU - Buadi, F. K. AU - Pandey, S. PY - 2014 DA - 2014// TI - Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.313 DO - 10.1038/leu.2013.313 ID - Kumar2014 ER - TY - JOUR AU - Benboubker, L. AU - Dimopoulos, M. A. AU - Dispenzieri, A. AU - Catalano, J. AU - Belch, A. R. AU - Cavo, M. PY - 2014 DA - 2014// TI - Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1402551 DO - 10.1056/NEJMoa1402551 ID - Benboubker2014 ER - TY - STD TI - Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459–66. ID - ref10 ER - TY - STD TI - Millennium Pharmaceuticals Inc. NINLARO® (ixazomib) capsules, for oral use. Prescribing information, November 2016. 2016. http://www.ninlaro.com/downloads/prescribing-information.pdf. Accessed 15 Dec 2016. UR - http://www.ninlaro.com/downloads/prescribing-information.pdf ID - ref11 ER - TY - STD TI - Takeda Pharma A/S. NINLARO® European Public Assessment Report - Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf. Accessed 15 Dec 2016. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf ID - ref12 ER - TY - JOUR AU - Moreau, P. AU - Masszi, T. AU - Grzasko, N. AU - Bahlis, N. J. AU - Hansson, M. AU - Pour, L. PY - 2016 DA - 2016// TI - Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1516282 DO - 10.1056/NEJMoa1516282 ID - Moreau2016 ER - TY - JOUR AU - Hou, J. AU - Du, X. AU - Jin, J. AU - Cai, Z. AU - Chen, F. AU - Zhou, D. B. PY - 2013 DA - 2013// TI - A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-41 DO - 10.1186/1756-8722-6-41 ID - Hou2013 ER - TY - JOUR AU - Greipp, P. R. AU - San Miguel, J. AU - Durie, B. G. AU - Crowley, J. J. AU - Barlogie, B. AU - Blade, J. PY - 2005 DA - 2005// TI - International staging system for multiple myeloma JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.04.242 DO - 10.1200/JCO.2005.04.242 ID - Greipp2005 ER - TY - JOUR AU - Rajkumar, S. V. AU - Harousseau, J. L. AU - Durie, B. AU - Anderson, K. C. AU - Dimopoulos, M. AU - Kyle, R. PY - 2011 DA - 2011// TI - Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-10-299487 DO - 10.1182/blood-2010-10-299487 ID - Rajkumar2011 ER - TY - JOUR AU - Agarwal, A. AU - Chow, E. AU - Bhutani, M. AU - Voorhees, P. M. AU - Friend, R. AU - Usmani, S. Z. PY - 2017 DA - 2017// TI - Practical considerations in managing relapsed multiple myeloma JO - Clin Lymphoma Myeloma Leuk VL - 17 UR - https://doi.org/10.1016/j.clml.2016.11.010 DO - 10.1016/j.clml.2016.11.010 ID - Agarwal2017 ER - TY - JOUR AU - Sonneveld, P. AU - Avet-Loiseau, H. AU - Lonial, S. AU - Usmani, S. AU - Siegel, D. AU - Anderson, K. C. PY - 2016 DA - 2016// TI - Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-01-631200 DO - 10.1182/blood-2016-01-631200 ID - Sonneveld2016 ER - TY - JOUR AU - Dimopoulos, M. A. AU - Oriol, A. AU - Nahi, H. AU - San-Miguel, J. AU - Bahlis, N. J. AU - Usmani, S. Z. PY - 2016 DA - 2016// TI - Daratumumab, lenalidomide, and dexamethasone for multiple myeloma JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1607751 DO - 10.1056/NEJMoa1607751 ID - Dimopoulos2016 ER - TY - JOUR AU - Lonial, S. AU - Dimopoulos, M. AU - Palumbo, A. AU - White, D. AU - Grosicki, S. AU - Spicka, I. PY - 2015 DA - 2015// TI - Elotuzumab therapy for relapsed or refractory multiple myeloma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1505654 DO - 10.1056/NEJMoa1505654 ID - Lonial2015 ER - TY - JOUR AU - Stewart, A. K. AU - Rajkumar, S. V. AU - Dimopoulos, M. A. AU - Masszi, T. AU - Spicka, I. AU - Oriol, A. PY - 2015 DA - 2015// TI - Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411321 DO - 10.1056/NEJMoa1411321 ID - Stewart2015 ER - TY - JOUR AU - Lonial, S. AU - Waller, E. K. AU - Richardson, P. G. AU - Jagannath, S. AU - Orlowski, R. Z. AU - Giver, C. R. PY - 2005 DA - 2005// TI - Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-03-1173 DO - 10.1182/blood-2005-03-1173 ID - Lonial2005 ER - TY - JOUR AU - Nooka, A. K. PY - 2013 DA - 2013// TI - Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib JO - Oncology (Williston Park) VL - 27 ID - Nooka2013 ER - TY - JOUR AU - Gupta, N. AU - Goh, Y. T. AU - Min, C. K. AU - Lee, J. H. AU - Kim, K. AU - Wong, R. S. PY - 2015 DA - 2015// TI - Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0198-1 DO - 10.1186/s13045-015-0198-1 ID - Gupta2015 ER - TY - JOUR AU - Kumar, S. K. AU - Bensinger, W. I. AU - Zimmerman, T. M. AU - Reeder, C. B. AU - Berenson, J. R. AU - Berg, D. PY - 2014 DA - 2014// TI - Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-548941 DO - 10.1182/blood-2014-01-548941 ID - Kumar2014 ER - TY - STD TI - Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, et al. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling. Clin Pharmacokinet. 2017. [Epub ahead of print]. doi:10.1007/s40262-017-0526-4. ID - ref26 ER - TY - JOUR AU - Gupta, N. AU - Zhao, Y. AU - Hui, A. M. AU - Esseltine, D. L. AU - Venkatakrishnan, K. PY - 2015 DA - 2015// TI - Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis JO - Br J Clin Pharmacol VL - 79 UR - https://doi.org/10.1111/bcp.12542 DO - 10.1111/bcp.12542 ID - Gupta2015 ER - TY - JOUR AU - Kurose, K. AU - Sugiyama, E. AU - Saito, Y. PY - 2012 DA - 2012// TI - Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development JO - Drug Metab Pharmacokinet VL - 27 UR - https://doi.org/10.2133/dmpk.DMPK-11-RV-111 DO - 10.2133/dmpk.DMPK-11-RV-111 ID - Kurose2012 ER - TY - JOUR AU - Ono, C. AU - Kikkawa, H. AU - Suzuki, A. AU - Suzuki, M. AU - Yamamoto, Y. AU - Ichikawa, K. PY - 2013 DA - 2013// TI - Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions JO - Pharmacogenomics VL - 14 UR - https://doi.org/10.2217/pgs.13.171 DO - 10.2217/pgs.13.171 ID - Ono2013 ER - TY - JOUR AU - Fricke-Galindo, I. AU - Cespedes-Garro, C. AU - Rodrigues-Soares, F. AU - Naranjo, M. E. AU - Delgado, A. AU - de Andrés, F. PY - 2016 DA - 2016// TI - Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations JO - Pharmacogenomics J VL - 16 UR - https://doi.org/10.1038/tpj.2015.70 DO - 10.1038/tpj.2015.70 ID - Fricke-Galindo2016 ER - TY - JOUR AU - Tomita, Y. AU - Maeda, K. AU - Sugiyama, Y. PY - 2013 DA - 2013// TI - Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism JO - Clin Pharmacol Ther VL - 94 UR - https://doi.org/10.1038/clpt.2012.221 DO - 10.1038/clpt.2012.221 ID - Tomita2013 ER -